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Intravenous (IV) fluid administration is a nearly ubiquitous 
intervention in hospitalised patients. It is used to maintain 
euvolaemia in fasting patients, to replace physiological and 
pathophysiological fluid losses, to deliver medications and 
to manage haemodynamic instability.1 The consumption of 
IV fluids is expected to increase, and the global market is 
expected to be worth an estimated $7.2 billion by 2017.2
Crystalloid solutions such as 0.9% sodium chloride 
solution, balanced solutions such as compound sodium 
lactate solution, and acetated solutions such as PlasmaLyte 
are used in a variety of clinical situations.3 Artificial colloid 
solutions such as substituted hydroxyethyl starch (HES) 
(Voluven, Volulyte and StarQuin), succinylated gelatin 
(Gelofusine) preparations, and natural colloids such as 
various albumin solutions are typically used for fluid 
resuscitation.4,5 The type of fluid used appears to vary 
depending on clinician preference, cost, local guidelines 
and availability, and clinical requirements.4-6 
Despite the importance of IV fluid therapy, it remains 
unclear whether and how fluid consumption varies in 
different regions and countries. It is also uncertain whether 
such differences in fluid consumption are of sufficient 
magnitude to warrant further investigation, or whether 
these differences are dependent on the type of fluid being 
investigated. Finally, there are no studies on how such 
changes have evolved over time. We aimed to describe the 
geographic and temporal differences in fluid consumption 
across Australia and New Zealand.
Methods
We conducted a retrospective ecological study examining 
current regional and temporal trends in fluid administration 
across Australia and New Zealand over the periods 
2012–2013 and 2013–2014. The human research ethics 
committees of Monash University and the Austin Hospital 
approved the study (CF14/2949-2014001616 and LNR/14/
Austin/408).
Data sources
Australian and New Zealand demographic data
National and state population data were accessed through 
the relevant government agency publications. For Australia, 
the state and territorial populations for 2012 and 2013 were 
taken from the Australian Bureau of Statistics December 
2014 demographic statistics release.7 We used the 2013 
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ABSTRACT
Objectives: To describe changes in the use of intravenous 
(IV) fluid by quantity and type in different regions of 
Australia and New Zealand.
Design, setting and participants: We conducted a 
retrospective ecological study examining regional and 
temporal trends in IV fluid consumption across Australia 
and New Zealand over the periods 2012–2013 and 2013–
2014, using national proprietary sales data as a surrogate 
for consumption, and demographic data from the public 
domain.
Results: More than 13.3 million litres of IV fluid were 
consumed in Australia and New Zealand in 2012–2013, 
and more than 13.9 million litres in 2013–2014, with 
colloid solutions accounting for < 2%. There was marked 
regional variation in consumption of fluids, by volumes and 
proportions used, when standardised to overall Australian 
and New Zealand values. There was no significant change 
in the overall volume of crystalloid solutions consumed but 
there was a significant decrease (9%; P = 0.02) in the ratio 
of unbalanced to balanced crystalloid solutions consumed. 
Consumption of all forms of colloid solutions decreased, 
with a 12% reduction overall (P = 0.02), primarily driven by 
a 67% reduction in the consumption of hydroxyethyl starch 
(HES) solutions.
Conclusions: The amount and type of IV fluid use, as 
determined by fluid sales, is highly variable across Australia 
and New Zealand. However, overall use of balanced 
crystalloid solutions is increasing and the use of HES has 
decreased dramatically.
Crit Care Resusc 2016; 18: 78–88
Population Estimates and Projections report from Statistics 
New Zealand to obtain data on the national population of 
New Zealand for 2012 and 2013.8
Australian and New Zealand fluid sales data
Data on sales of crystalloids and artificial colloids in New 
Zealand and Australia over the periods 1 June 2012 to 31 
May 2013 and 1 June 2013 to 31 May 2014 were obtained 
from Baxter Healthcare (Sydney, NSW, Australia). These data 
were used as a surrogate for fluid consumption. The data 
were originally collected by IMS Health (Danbury, Conn, 
United States), a large information technology company 
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that specialises in provision of detailed health care data 
from more than 100 000 suppliers in over 100 countries to 
commercial and health care services. These are likely to be 
the most comprehensive sales data available, covering the 
entire IV fluid sector. Baxter Healthcare paid for data from 
IMS to use for sales forecasting purposes and market share 
estimation, which is standard practice in the health care 
industry. No information was available on 5% dextrose, 
4% dextrose/0.18% saline or hypertonic saline. Baxter 
Healthcare provided us with these data for the purposes 
of this research. Within Australia and New Zealand, Baxter 
Healthcare is the sole supplier of crystalloids but not of 
colloids. CSL is the sole supplier of albumin solutions, 
Fresenius-Kabi is the sole supplier of starch solutions, and 
B. Braun is the sole supplier of gelatin solutions.
Baxter Healthcare, using proprietary predictive modelling, 
imputed the artificial colloid sales data for New Zealand over 
the 2013–2014 period. As the same regional administration 
and sales team provides service in the Australian Capital 
Territory and New South Wales, Baxter Healthcare 
amalgamated the data for these two regions. Regional 
data for New Zealand were unavailable and it was treated 
as a single administrative area. Data were corrected for 
veterinary sales where possible; these were only available at 
a national level, and only for crystalloid solutions. 
In Australia, naturally derived colloid solutions of 4% and 
20% human albumin are freely available from the Australian 
Red Cross Blood Service as a by-product of blood product 
manufacture. We obtained data on their delivery from the 
Red Cross, the National Blood Authority and CSL.
Data handling
The total volume of crystalloids and colloids purchased 
in both Australia and New Zealand was calculated by 
multiplying the volume per unit by the number of units sold. 
This was repeated for New Zealand alone and the individual 
states and territories, and for each individual type of fluid. 
The volume purchased per capita was also calculated. 
Table 1. Population demographics and gross intravenous fluid sales (L), by region and fluid type
 Crystalloid solutions* Colloid solutions 
      Total 20%  4%    Total Total 
Region Population† Saline‡ CSL Acetate§ crystalloids albumin¶ albumin** Gelofusine†† Starch‡‡ colloids fluids
2012–2013           
NZ 4 435 700 1 071 466 301 208 372 627 1 745 301 873 5 447 6 815 10 974 24 108 1 769 409
AUS 22 917 637 7 350 401 3 835 018 201 513 11 386 932 14 903 112 922 48 677 25 967 202 468 11 589 400
 ACT, NSW 7 734 777 2 518 316 1 455 359 83 226 4 056 901 5 341 31 134 6 863 8 422 51 759 4 108 660
 VIC 5 680 502 17 44 769 1 101 160 15 819 2 861 748 3 474 26 891 12 514 8 621 51 499 2 913 246
 QLD 4 608 886 1 782 600 791 441 87 573 2 661 614 3 291 32 456 5 116 4 648 45 510 2 707124
 WA 2 479 506 645 643 506 603 6 633 1 158 879 1 111 6 862 15 636 3 614 27 223 1 186 102
 SA 1 662 197 501 012 249 570 7 224 757 806 1 263 12 514 7 957 590 22 324 780 130
 TAS 512 475 206 249 119 829 804 326 882 290 2 028 492 73 2 884 329 766
 NT 239 294 112 889 19 683 7 080 139 652 132 1 037 100 0 1 269 140 921
AUS and NZ 27 353 337 8 421 867 4 136 226 574 140 13 132 232 15 776 118 369 55 491 36 941 226 577 13 358 809
2013–2014            
NZ 4 475 100 1 231 277 381 663 431 465 2 044 405 993 6 184 5 111 6 807 19 095 2 063 500
AUS 23 307 564 7 314 712 4 144 483 279 977 11 739 172 14 913 115 567 46 375 5 554 182 408 11 921 580
 ACT, NSW 7 849 120 2 540 654 1 612 889 100 613 4 254 155 5 397 29 701 5 962 3 338 44 397 4 298 552
 VIC 5 787 086 1 642 750 1 100 928 20 019 2 763 697 3 428 29 608 12 283 734 46 051 2 809 748
 QLD 4 687 417 1 735 309 870 888 122 829 2 729 026 3 115 34 416 5 519 927 43 976 2 773 002
 WA 2 549 145 650 281 556 551 11 184 1 218 016 1 105 6 930 15 416 422 23 873 1 241 888
 SA 1 67 7062 581 263 281 815 10 740 873 818 1 360 11 941 6 498 127 19 926 893 744
 TAS 513 927 202 718 128 363 996 332 077 357 2 105 627 7 3 095 335 172
 NT 243 807 119 090 20 943 19 836 159 869 153 868 70 0 1 090 160 959
AUS and NZ 27 782 664 8 545 989 4 526 146 711 442 13 783 577 15 906 121 751 51 486 12 360 201 503 13 985 080
CSL = compound sodium lactate. NZ = New Zealand. AUS = Australia. ACT = Australian Capital Territory. NSW = New South Wales. VIC = Victoria.  
QLD = Queensland. WA = Western Australia. SA = South Australia. TAS = Tasmania. NT = Northern Territory. * Australian, NZ, and Australian + NZ 
crystalloid values adjusted to account for national sales to veterinary agencies. † From government data. ‡ 0.9% sodium chloride solution.  
§ PlasmaLyte (proprietary acetated solution). ¶ 20% human albumin solution. ** 4% human albumin solution. †† 4% succinylated gelatin solution.  
‡‡ 6% hydroxyethyl starch + 10% pentastarch.
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For the purposes of comparison, total fluid sales across 
the whole of Australia and New Zealand were treated as 
the index population. Sales of Hartmann’s solution and 
compound sodium lactate solution were combined under 
the heading of compound sodium lactate, and Voluven, 
Volulyte and StarQuin 6% solution sales, as well as sales 
of a very small quantity of pentastarch in New Zealand in 
2012–2013, were combined under the heading of starch.
Statistical analysis
We performed statistical analyses using Stata, version 
13 (StataCorp) and calculated simple proportions and 
percentages. The Wilcoxon signed-rank test was used to 
identify significant differences in the sales of each fluid type 
between the two periods across all regions. A two-sided P 
value of 0.05 was considered to be statistically significant.
Results
Demographics and gross fluid sales data
The gross national and regional fluid sales and population 
data are shown in Table 1. More than 13.3 million litres 
of IV fluid were sold (and probably consumed) in Australia 
and New Zealand in the 2012–2013 period, and more than 
13.9 million litres in 2013–2014. Crystalloid sales dwarfed 
colloid sales, with only 227 000 L of colloid fluids being 
consumed in 2012–2013 and 201 000 L in 2013–2014 
(Table 1, Figure 1).
Regional differences in overall fluid consumption
The consumption of fluid varied in quantity and composition 
for the 2012–2013 and 2013–2014 periods according to 
region. The relative proportions of the individual fluid types 
consumed in each region over these periods are shown 
graphically in Figures 1 and 2. In 2012–2013, 523 mL of IV 
fluid were consumed per capita among the whole Australian 
and New Zealand population, and in 2013–2014, 488 mL 
were consumed per capita. The variation in consumption 
between regions when standardised to overall Australian 
and New Zealand values was marked, with New Zealand 
consuming 18% less IV fluid, and Tasmania consuming 
32% more during the same period. Similarly variable results 
were obtained from 2013–2014 data (Tables 2 and 3). 
Regional differences in crystalloid consumption
The volume and composition of crystalloid solutions varied 
between regions in both periods. The regional standardised 
volume of crystalloids consumed per capita varied between 
82% and 133% of overall Australian and New Zealand 
consumption in 2012–2013, and between 92% and 133% 
in 2013–2014 (Tables 2 and 3, Figure 2). The proportional 
use of crystalloid fluid types varied markedly between 
regions in both periods. The consumption of acetated 
solutions in New Zealand was 400% greater than their 
overall consumption across Australia and New Zealand in 
2012–2013, but was 90% less in Tasmania, with a similar 
variation seen in 2013–2014. The ratio of unbalanced to 
Figure 1. Intravenous fluid consumption per  
capita, by region, 2012–2013 and 2013–2014
* NZ = New Zealand. AUS = Australia. ACT = Australian 
Capital Territory. NSW = New South Wales. QLD = Queensland. 
WA = Western Australia. SA = South Australia. TAS = Tasmania. 
NT = Northern Territory. 13 = 2012–2013. 14 = 2013–2014. 
A. Total volume of crystalloid and colloid solutions. B. Total volume 
of acetated solutions, lactated salt solutions and 0.9% sodium 
chloride solutions. C. Total volume of 20% albumin solutions, 
4% albumin solutions, 6% hydroxyethyl starch solutions, 10% 
pentastarch and 4% succinylated gelatin solutions. 
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Figure 2. Regional consumption of crystalloid solutions in Australia and New Zealand, by fluid type  
(estimated by sales per capita), 2012–2013 and 2013–2014
* NZ = New Zealand. AUS = Australia. ACT = Australian Capital Territory. NSW = New South Wales. QLD = Queensland. WA = Western Australia. 
SA = South Australia. TAS = Tasmania. NT = Northern Territory. 13 = 2012–2013. 14 = 2013–2014. 
A. Saline = 0.9% sodium chloride solution. B. CSL = compound sodium lactate. C. Acetate = PlasmaLyte (proprietary acetated solution).  
D. U:B = ratio of unbalanced to balanced crystalloid solutions.  
balanced crystalloid solutions consumed varied from 87% 
to 236% of the overall Australian and New Zealand values 
in 2012–2013, and from 71% to 179% of these values in 
2013–2014. 
Regional differences in colloid consumption
The volume and composition of colloid solutions varied 
markedly between regions in both periods. The regional 
standardised volume of colloids consumed per capita 
varied from 64% to 162% of overall Australian and New 
Zealand consumption in 2012–2013, with similar variations 
in 2013–2014 (Tables 2 and 3, Figure 3). The proportional 
use of differing colloid types varied markedly between 
regions over the two time periods. The consumption of 
starch solutions in New Zealand was 183% that of Australia 
and New Zealand overall in 2012–2013, and 345% that of 
Australia and New Zealand overall in 2013–2014. The ratio 
of natural colloid solutions (albumin) to synthetic colloid 
solutions (gelatins and starches) used varied from 25% to 
806% of the standardised Australian and New Zealand 
values in 2012–2013, and from 28% to 675% of the 2013–
2014 Australian and New Zealand values. Artificial colloid 
use was dominant in New Zealand, but albumin solutions 
appeared to be more popular across Australia. No starch 
was used in the Northern Territory in either period (Tables 
2 and 3).
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Temporal changes in overall fluid consumption
Across Australia and New Zealand between 2012–2013 and 
2013–2014, there was an increase in IV fluid consumption 
of approximately 626 000 L, a gross increase of 5% but a 
statistically non-significant increase of only 3% in per-capita 
terms (Figure 4, Table 1, Table 4). 
Temporal changes in crystalloid consumption
Although there was no statistically significant increase in 
the total volume of crystalloid sold per capita between 
the two periods, there was a significant increase in the 
consumption of lactated solutions (7%; P = 0.02) and 
acetated solutions (24%; P = 0.02) in Australia and New 
Zealand. This translated into a 9% decrease (P = 0.02) in 
the ratio of unbalanced to balanced crystalloid solutions 
consumed between the two periods (Figure 4, Table 4).
Temporal changes in colloid consumption
Total colloid sales per hospital admission decreased by 12% 
between 2012–2013 and 2013–2014 (P = 0.02). This was 
primarily driven by a huge reduction in the consumption of 
starch (Figure 4, Table 4).
Discussion
Key findings
Using regional and national fluid sales data as a surrogate 
measure of fluid consumption, we describe the first 
published estimate of IV fluid use at a national level, for two 
countries. We make several new and important observations. 
First, we show that the consumption of crystalloids across 
Australia and New Zealand is orders of magnitude greater 
than the consumption of colloids. Second, patterns of 
Table 2. Intravenous fluid consumption 2012–2013, volumes per capita and volumes standardised to  
Australian and New Zealand overall values
 Crystalloid solutions* Colloid solutions 
      Total 20%  4%    Total Total 
Region Saline† CSL Acetate‡ U:B§ crystalloids albumin¶ albumin** Gelofusine†† Starch‡‡ N:S§§ colloids fluids
Fluid sold, mL/capita
NZ 242 68 84 1.59 393 0.2 1.23 1.54 2.47 0.36 5.44 399
Australia 321 167 9 1.82 497 0.65 4.93 2.12 1.13 1.71 8.83 506
 ACT/NSW 326 188 11 1.64 525 0.69 4.03 0.89 1.09 2.39 6.69 531
 VIC 307 194 3 1.56 504 0.61 4.73 2.2 1.52 1.44 9.07 513
 QLD 387 172 19 2.03 577 0.71 7.04 1.11 1.01 3.66 9.87 587
 WA 260 204 3 1.26 467 0.45 2.77 6.31 1.46 0.41 10.98 478
 SA 301 150 4 1.95 456 0.76 7.53 4.79 0.35 1.61 13.43 469
 TAS 402 234 2 1.71 638 0.57 3.96 0.96 0.14 4.1 5.63 643
 NT 472 82 30 4.22 584 0.55 4.33 0.42 0 11.69 5.3 589
Australia and NZ 308 151 21 1.79 480 0.58 4.33 2.03 1.35 1.45 8.28 488
Fluid totals (ratios, standardised to Australian and New Zealand volumes)    
NZ 0.79 0.45 4 0.89 0.82 0.34 0.28 0.76 1.83 0.25 0.66 0.82
Australia 1.04 1.11 0.43 1.02 1.04 1.12 1.14 1.04 0.84 1.18 1.07 1.04
 ACT/NSW 1.06 1.25 0.52 0.92 1.09 1.19 0.93 0.44 0.81 1.65 0.81 1.09
 VIC 1 1.28 0.14 0.87 1.05 1.05 1.09 1.08 1.13 0.99 1.1 1.05
 QLD 1.26 1.14 0.9 1.13 1.2 1.22 1.63 0.55 0.75 2.52 1.19 1.2
 WA 0.84 1.35 0.14 0.7 0.97 0.78 0.64 3.11 1.08 0.28 1.33 0.98
 SA 0.98 0.99 0.19 1.09 0.95 1.31 1.74 2.36 0.26 1.11 1.62 0.96
 TAS 1.31 1.55 0.1 0.96 1.33 0.98 0.91 0.47 0.1 2.83 0.68 1.32
 NT 1.53 0.54 1.43 2.36 1.22 0.95 1 0.21 0 8.06 0.64 1.21
Australia and NZ 1 1 1 1 1 1 1 1 1 1 1 1
CSL = compound sodium lactate. NZ = New Zealand. ACT = Australian Capital Territory. NSW = New South Wales. VIC = Victoria. QLD = 
Queensland. WA = Western Australia. SA = South Australia. TAS = Tasmania. NT = Northern Territory. * Australian, NZ, and Australian + NZ 
crystalloid values adjusted to account for national sales to veterinary agencies. † 0.9% sodium chloride solution. ‡ PlasmaLyte (proprietary 
acetated solution). § Ratio of unbalanced to balanced crystalloid solution consumption. ¶ 20% human albumin solution. ** 4% human albumin 
solution. †† 4% succinylated gelatin solution. ‡‡ 6% hydroxyethyl starch + 10% pentastarch. §§ Ratio of natural (albumin) to synthetic (gelatin 
and starch) colloid consumption.
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fluid consumption are highly variable across Australia and 
New Zealand, with different crystalloids and colloids being 
used in different proportions and different total volumes in 
different regions in an apparently chaotic fashion. Acetated 
solutions, albumin solutions and 6% HES solutions, in 
particular, show massive regional variations in consumption 
over the study periods. Third, the ratio of unbalanced to 
balanced crystalloid consumption is falling in every region, 
suggesting that there is a widespread increasing preference 
for such balanced solutions over saline. Fourth, we show 
significant reductions in the sale of colloid solutions over a 
2-year period, and a two-thirds decrease in the consumption 
of starch solutions, a finding congruent with recent trials 
showing toxicity.
Study findings in context
To our knowledge, this is the first published description of 
fluid administration at a bi-national level across two entire 
health services. The National Health Service of the United 
Kingdom spends about £156 million on IV fluids each year,9 
and the only previously published estimate of IV fluid sales 
in the medical literature10 suggests that the UK purchases 
10 million litres of saline annually. In Australia and New 
Zealand, more than 13 million litres are purchased, despite 
having a combined population less than half the size, while 
the US purchases 200 million litres.10 We were unable to 
identify information in the medical literature about temporal 
trends in fluid sales or use at a national level in the US.
Our description of fluid consumption patterns shows 
significant regional variation in IV fluid use. Such an 
inconsistent approach to fluid use has been described 
tangentially in other contexts. In 1994, world consumption 
of colloid solutions was 48.33 million units. Of these, 
31.4% were albumin solutions (37.7% in New Zealand 
and 71.6% in Australia in 2013–2014); 44.9% were 
dextrans and starches (35.7% in New Zealand and 3.1% 
Table 3. Intravenous fluid consumption 2013–2014, volumes per capita and volumes standardised to  
Australian and New Zealand overall values
 Crystalloid solutions* Colloid solutions 
      Total 20% 4%    Total Total 
Region Saline† CSL Acetate‡ U:B§ crystalloids albumin¶ albumin** Gelofusine†† Starch‡‡ N:S§§ colloids fluids
Fluid sold, mL/capita           
NZ 275 85 96 1.51 457 0.22 1.38 1.14 1.52 0.6 4.27 461
Australia 314 178 12 1.65 504 0.64 4.96 1.99 0.24 2.51 7.83 511
ACT/NSW 324 205 13 1.48 542 0.69 3.78 0.76 0.43 3.77 5.66 548
VIC 284 190 3 1.47 478 0.59 5.12 2.12 0.13 2.54 7.96 486
QLD 370 186 26 1.75 582 0.66 7.34 1.18 0.2 5.82 9.38 592
WA 255 218 4 1.15 478 0.43 2.72 6.05 0.17 0.51 9.37 487
SA 347 168 6 1.99 521 0.81 7.12 3.87 0.08 2.01 11.88 533
TAS 394 250 2 1.57 646 0.69 4.1 1.22 0.01 3.89 6.02 652
NT 488 86 81 2.92 656 0.63 3.56 0.29 0 14.57 4.47 660
Australia and NZ 308 163 26 1.63 496 0.57 4.38 1.85 0.44 2.16 7.25 503
Fluid totals (ratios, standardised to Australian and New Zealand volumes)
NZ 0.89 0.52 3.69 0.93 0.92 0.39 0.32 0.62 3.45 0.28 0.59 0.92
Australia 1.02 1.09 0.46 1.01 1.02 1.12 1.13 1.08 0.55 1.16 1.08 1.02
ACT/NSW 1.05 1.26 0.5 0.91 1.09 1.21 0.86 0.41 0.98 1.75 0.78 1.09
VIC 0.92 1.17 0.12 0.9 0.96 1.04 1.17 1.15 0.3 1.18 1.1 0.97
QLD 1.2 1.14 1 1.07 1.17 1.16 1.68 0.64 0.45 2.69 1.29 1.18
WA 0.83 1.34 0.15 0.71 0.96 0.75 0.62 3.27 0.39 0.24 1.29 0.97
SA 1.13 1.03 0.23 1.22 1.05 1.42 1.63 2.09 0.18 0.93 1.64 1.06
TAS 1.28 1.53 0.08 0.96 1.3 1.21 0.94 0.66 0.02 1.8 0.83 1.3
NT 1.58 0.53 3.12 1.79 1.32 1.11 0.81 0.16 0 6.75 0.62 1.31
Australia and NZ 1 1 1 1 1 1 1 1 1 1 1 1
CSL = compound sodium lactate. NZ = New Zealand. ACT = Australian Capital Territory. NSW = New South Wales. VIC = Victoria.  
QLD = Queensland. WA = Western Australia. SA = South Australia. TAS = Tasmania. NT = Northern Territory. * Australian, NZ, and Australian  
+ NZ crystalloid values adjusted to account for national sales to veterinary agencies. † 0.9% sodium chloride solution. ‡ PlasmaLyte (proprietary 
acetated solution). § Ratio of unbalanced to balanced crystalloid solution consumption. ¶ 20% human albumin solution. ** 4% human albumin 
solution. †† 4% succinylated gelatin solution. ‡‡ 6% hydroxyethyl starch + 10% pentastarch. §§ Ratio of natural (albumin) to synthetic (gelatin 
and starch) colloid consumption.
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Figure 3. Regional consumption of colloid solutions in Australia and New Zealand, by fluid type  
(estimated by sales per capita), 2012–2013 and 2013–2014
A. 20% albumin = 20% human albumin solutions. B. 4% albumin = 4% human albumin solutions. C. Gelofusine = 4% succinylated gelatin 
solutions. D. Starch = 6% hydroxyethyl starch + 10% pentastarch. 13 = 2012–2013. 14 = 2013–2014.  * NZ = New Zealand. AUS = Australia. 
ACT = Australian Capital Territory. NSW = New South Wales. QLD = Queensland. WA = Western Australia. SA = South Australia. TAS = Tasmania. 
NT = Northern Territory. 
in Australia); 9.3% were gelatins (26.8% in New Zealand 
and 25.5% in Australia); and 4.9% were other solutions.11 
By comparison, the UK over the same period consumed 
1.54 million units of colloid, 68% of which were gelatins.11 
An international cross-sectional study of fluid resuscitation 
in 391 intensive care units showed marked international 
variability in the types of fluid used in the acute care setting.6 
Recent Australian and New Zealand studies of paediatric 
emergency physicians12 and adult emergency physicians 
and intensivists13 also confirm that this inconsistency is likely 
to exist at an individual, as well as a regional, level. There 
is a marked paucity of information on the preferences of 
prescribing specialists outside these areas, although similar 
variability is likely to be present on general adult medical 
and surgical wards.14-18
 The use of balanced or buffered solutions is not 
new,19-24 but the administration of such quantities of 
salt had been of concern since the inception of IV fluid 
experimentation.25 Recent evidence has highlighted the 
potential adverse physiological, and possibly clinical, effects 
of excess sodium26 and chloride administration.10,27-31 
The use of balanced solutions has been shown, on meta-
analysis of small trials of surgical patients, to be safe and 
associated with an improved perioperative metabolic profile 
when compared with non-physiological solutions.32 To our 
knowledge, ours is the first high-level demonstration of a 
changing, widespread bi-national preference for balanced 
crystalloid fluids over saline, a finding that is consistent with 
recent reports of changing preferences for resuscitation 
fluids in ICUs in Australia and New Zealand.33
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Colloid solutions have been used in acute care for a 
century34 and there has long been controversy about their 
role.35-36 However, given the modern understanding of 
microvascular fluid dynamics,37 the intravascular persistence 
of colloids is likely to be limited. It is also possible that 
fluid resuscitation itself may disrupt the glycocalyx, further 
altering the transvascular equilibrium in states of acute 
illness.38 Clinical evidence has shown that replacement of 
colloids with crystalloids occurs with a 1:1.3 ratio instead of 
the 1:3 ratio that has been postulated by advocates of the 
traditional Starling hypothesis.5 
We show that in Australia and New Zealand, the use 
of colloid solutions is falling,33 primarily due to decreased 
consumption of starch-containing fluids in response to 
large, randomised controlled trials conducted in Australia 
and New Zealand,39 and elsewhere,40,41 showing harm.42 
For the first time, we show the effect of these studies in 
real terms across the entire health service as evidence of 
translation of research into widespread practice.
Study implications
Our findings imply that there are unexplained major regional 
practice variations in the use of fluids. Acetated solutions, 
albumin solutions, and 6% HES solutions, in particular, show 
massive regional variation in consumption over the periods 
of the study, with threefold differences within Australia 
and up to sixfold differences between Australia and New 
Zealand. This implies that regional factors overcome 
evidence-based considerations.39,42,43
The ratio of unbalanced to balanced crystalloid use 
is falling in every region, which implies that there is a 
widespread shift away from saline use. This shift, involving 
millions of litres and probably thousands to millions of 
patient exposures, leads us to believe that large, double-
blind, randomised controlled trials are needed to define 
whether such changes are justified.44 New physiological 
solutions are in development for use in humans, and these 
will require extensive testing before being introduced.45
Finally, the significant reduction in the sale of artificial 
colloid solutions and the two-thirds decrease in the 
consumption of starch solutions show that clinicians do 
respond to high-quality evidence when present. These 
changes are also high-level, bi-national evidence of 
translation of research into practice. They also show the 
impact and value of the National Health and Medical 
Research Council-funded Crystalloid versus Hydroxyethyl 
Starch Trial (CHEST) in driving practice change, with the 
20 000 L decrease in starch use leading to approximately 
$460 000 in annual savings in health care expenditure in 
Australia alone.39,42
Figure 4. Temporal percentage changes in overall fluid consumption by fluid type in Australia and New 
Zealand, 2012–2013 and 2013–2014
Relative difference between fluid consumption as measured by fluid sales, by fluid type, between 2012–13 and 2013–14. Saline = 0.9% sodium 
chloride solution. CSL = compound sodium lactate. Acetate = PlasmaLyte (proprietary acetated solution). U:B ratio = ratio of unbalanced to 
balanced crystalloid consumption. 20% Albumin = 20% human albumin solution. 4% Albumin = 4% human albumin solution. Gelofusine = 4% 
succinylated gelatin solution. HES = 6% hydroxyethyl starch. N:S ratio = ratio of natural (albumin) to synthetic (gelatin and starch) colloid 
consumption. * P < 0.05 for change over all regions between the two time points.
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Limitations
Ours was an ecological study using census and government 
data, so had the limitations associated with this study 
design. We were unable to identify from this ecological 
data where these fluids were used, and there is likely to 
be significant variation between the fluids consumed in 
operating theatres and those consumed on the ward or 
in the emergency department or ICU. We do not know 
the factors that might have influenced the purchasing of 
fluids at a regional or individual hospital level, and the 
complexities of health care procurement make controlling 
for such factors nearly impossible. However, such factors 
may include emerging evidence, staff preference, changes 
in pricing or marketing strategy, and local or national 
changes in policy.
Given that we used proprietary sales data as a surrogate 
for actual use, our results may not accurately reflect the 
administration of fluids. However, it is unlikely that significant 
quantities of fluid are purchased but not used, and this 
methodology is unlikely to introduce significant bias. By using 
a per-capita rather than a per-hospital admission approach to 
consumption, and by correcting for veterinary sales where 
we were able to, we aimed to limit additional bias.
Conclusions
Ours was the first study of IV fluid sales as a surrogate of 
consumption at a bi-national level across two entire health 
services. We found that use was highly variable in Australia 
and New Zealand, with different crystalloid and colloid 
solutions being used in different proportions and different 
total volumes in different regions in a seemingly chaotic 
fashion. We found major regional variations in consumption 
of acetated solutions, albumin solutions and 6% HES 
solutions in particular over the study period. A widespread 
increasing preference for balanced solutions over saline was 
suggested by the falling ratio of unbalanced to balanced 
crystalloid use. Finally, we showed significant reductions 
in the consumption of starch solutions, a finding that fits 
with recent concerns about its safety. Our findings provide 
an up-to-date, bi-national insight into this fundamental 
component of medical practice across health services; imply 
that there is a need for trials comparing balanced solutions 
with saline; and provide a benchmark for the assessment of 
translation of research into practice.
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training developed by the New South Wales Organ and
Tissue Donation Service provide forums for practical role
play-style training. This training has been shown in other
countries to improve the quality of the communication as
reported by families and requesters, as well as the consent
rates.12 We expect that this training would be repeated as a
skills refresher on a regular basis. The OTA is now develop-
ing advanced FDC modules to build family support and
requesting skills in specialist areas such as in the situation of
a paediatric donor.
Countries with the highest consent rates, such as Spain
(85%) and the United States (75%), largely attribute their
success to having skilled, experienced dedicated request-
ers.3,8 In Spain, these are intensivists who work part-time in
medical donation coordinator roles. In the US, organ pro-
curement organisation-employed nurses or requesters who
are not health care trained attend the hospital to manage
the family communication.
It is no longer reasonable to as ume that untrained
intensivi ts are best placed to independently manage FDCs.
Intensivists should consider undertaking the cor  and prac-
tical FDC training nd, together with their local hospital
donation specialist colleagues and donation agencies,
determine whether a select pool of requesters (medical and/
or nursing) should be routinely called on to undertake this
specialised communication with families of potential
donors.
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